PORTFOLIO NEWS Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236 June 28, 2022 Read More » NGM Bio to Host the Final of Four Virtual R&D Events on June 29, 2022 June 23, 2022 Read More » Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting June 17, 2022 Read More » Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics June 16, 2022 Read More » Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis June 13, 2022 Read More » eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity June 5, 2022 Read More » Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development May 26, 2022 Read More » Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy May 26, 2022 Read More » RAPT Therapeutics Announces Private Placement Financing of $50 Million May 25, 2022 Read More » NGM Bio to Host the Third of Four Virtual R&D Events on May 31, 2022 May 24, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236 June 28, 2022 Read More »
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting June 17, 2022 Read More »
Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics June 16, 2022 Read More »
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis June 13, 2022 Read More »
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity June 5, 2022 Read More »
Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development May 26, 2022 Read More »
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy May 26, 2022 Read More »
